Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
Listing Date2022/12/15
Listing Price24.980
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    7 lot
  • One Lot Success Rate

3D Medicines founded in 2014, it is a bio-pharmaceutical company focusing on the research and development of oncology therapies for require long-term care cancer patients. Its core business model is to develop and commercialize oncology products and drug candidates through a combination of co-development, in-licensing and in-house discovery.


As of 21 Nov 2022, the Group have built a pipeline consisting of one Core Product and 11 drug candidates, among which, the Core Product envafolimab (brand name: ENWEIDA, 恩維達), as its backbone, was approved in November 2021 and commercialized in December 2021, and seven other drug candidates are in clinical stage.


The Group started to generate revenue from the sales of envafolimab to pharmacy operating companies and distributors. Its customers covered 30 provinces and municipalities in China. It has been building its in-house production facilities in Xuzhou, Jiangsu province. It expects to complete building the facilities and commence operation by 2024.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
No. of Offer Shares16.35M shares
No. of International Offer Shares14.72M shares
No. of HK Offer Shares1.64M shares
Offer Price$22.96 - $26.24
Stock Code1244
Sponsor(s)China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited
Underwriter(s)China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited, CNCB (Hong Kong) Capital Limited, CCB International Capital Limited, Huarong International Securities Limited, Livermore Holdings Limited, ABCI Securities Company Limited, Tiger Brokers (HK) Global Limited, SDHG International Securities Limited, Lego Securities Limited, Valuable Capital Limited, Futu Securities International (Hong Kong) Limited, Victory Securities Company Limited
Application PeriodNov 29 (Tue) - noon, Dec 07 (Wed)
Price Determination DateDec 07 (Wed)
Result Announcement DateOn or before Dec 14 (Wed)
Result Announcement DateOn or before Nov 14 (Mon)
Dealings in Shares commence onDec 15, 2022. (Thu)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$22.96 - $26.24
Capitalization5.87B - 6.71B
NAV / share ($)$5.11 - $5.35 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 24.6, the net proceeds raised would be HKD 245.00M, of which
55% : Used for our Core Product envafolimab
25% : Used for our other drug candidates, including 3D229, 3D011 and 3D185
10% : Construction of in-house production facilities in Xuzhou, Jiangsu province
10% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.